Q2 2024 EPS Estimates for Bausch Health Companies Inc. Cut by Zacks Research (NYSE:BHC)

Bausch Health Companies Inc. (NYSE:BHC) – Equities research analysts at Zacks Research lowered their Q2 2024 earnings estimates for shares of Bausch Health Companies in a report issued on Thursday, May 23rd. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.86 for the quarter, down from their prior estimate of $0.93. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.63 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2024 earnings at $1.02 EPS, FY2024 earnings at $3.57 EPS, Q1 2025 earnings at $0.82 EPS, Q4 2025 earnings at $1.30 EPS and FY2025 earnings at $4.16 EPS.

Several other research firms have also commented on BHC. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Jefferies Financial Group reduced their target price on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. Piper Sandler increased their price objective on shares of Bausch Health Companies from $7.00 to $9.00 and gave the company a “neutral” rating in a research note on Monday, April 29th. Finally, Royal Bank of Canada decreased their price objective on Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating on the stock in a research note on Tuesday, April 23rd. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $11.33.

Bausch Health Companies Trading Up 0.2 %

Shares of NYSE BHC opened at $6.36 on Monday. The stock has a market cap of $2.33 billion, a P/E ratio of -5.13 and a beta of 0.90. The business’s fifty day simple moving average is $8.54 and its 200-day simple moving average is $8.19. Bausch Health Companies has a 12-month low of $6.26 and a 12-month high of $11.46.

Bausch Health Companies (NYSE:BHC) last posted its earnings results on Thursday, May 2nd. The company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.16). Bausch Health Companies had a negative return on equity of 2,370.91% and a negative net margin of 5.07%. The firm had revenue of $2.15 billion for the quarter, compared to analyst estimates of $2.18 billion.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BHC. Nomura Holdings Inc. raised its holdings in Bausch Health Companies by 67.7% during the third quarter. Nomura Holdings Inc. now owns 18,086,000 shares of the company’s stock valued at $148,667,000 after buying an additional 7,303,015 shares in the last quarter. Mizuho Markets Americas LLC acquired a new position in shares of Bausch Health Companies during the third quarter worth approximately $57,540,000. Goldentree Asset Management LP boosted its position in shares of Bausch Health Companies by 19.6% in the third quarter. Goldentree Asset Management LP now owns 23,987,462 shares of the company’s stock valued at $197,177,000 after acquiring an additional 3,931,234 shares during the period. Norges Bank bought a new stake in Bausch Health Companies in the 4th quarter valued at $31,121,000. Finally, Hillsdale Investment Management Inc. increased its holdings in shares of Bausch Health Companies by 1,050.8% during the 1st quarter. Hillsdale Investment Management Inc. now owns 3,409,383 shares of the company’s stock worth $36,135,000 after purchasing an additional 3,113,123 shares during the period. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.